Evidence map›Paper›PMID 25085655›Full record

ArticleThe Journal of antimicrobial chemotherapy2014

Lethal synergy involving bicyclomycin: an approach for reviving old antibiotics.

Muhammad Malik, Liping Li, Xilin Zhao, Robert J Kerns, James M Berger, Karl Drlica

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of antimicrobial chemotherapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.5field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 34 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Bacterial Transcription as a Target for Antibacterial Drug Development.Microbiology and molecular biology reviews : MMBR · 2016
    Review
  14. Review
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Muhammad MalikPublic Health Research Institute, New Jersey Medical School, Rutgers Biomedical and Health Sciences, 225 Warren St., Newark, NJ, USA.
Liping LiPublic Health Research Institute, New Jersey Medical School, Rutgers Biomedical and Health Sciences, 225 Warren St., Newark, NJ, USA.
Xilin ZhaoPublic Health Research Institute, New Jersey Medical School, Rutgers Biomedical and Health Sciences, 225 Warren St., Newark, NJ, USA Department of Microbiology and Molecular Genetics, New Jersey Medical School, Rutgers Biomedical and Health Sciences, 225 Warren St., Newark, NJ, USA.
Robert J KernsDivision of Medicinal and Natural Products Chemistry, College of Pharmacy, University of Iowa, Iowa City, IA 52246, USA.
James M BergerMolecular and Cell Biology Department, Quantitative Biosciences Institute, University of California, Berkeley, CA 94720, USA.
Karl DrlicaPublic Health Research Institute, New Jersey Medical School, Rutgers Biomedical and Health Sciences, 225 Warren St., Newark, NJ, USA Department of Microbiology and Molecular Genetics, New Jersey Medical School, Rutgers Biomedical and Health Sciences, 225 Warren St., Newark, NJ, USA drlicaka@njms.rutgers.edu.
Rutgers Health · USRutgers, The State University of New Jersey · USUniversity of California, Berkeley · USUniversity of Iowa · US

Funding

Novel fluoroquinolones for killing dormant Mycobacterium tuberculosisR01AI073491 · NIAID · UNIV OF MED/DENT OF NJ-NJ MEDICAL SCHOOL · PI DRLICA, KARL A, KERNS, ROBERT JOHN · 2007 to 2015
$5.1M
Anaerobic shock as a novel treatment for tuberculosisDP2OD007423 · OD · UNIV OF MED/DENT OF NJ-NJ MEDICAL SCHOOL · PI ZHAO, XILIN · 2010 to 2010
$2.3M
Antibacterial Agents that Restrict the Emergence of ResistanceR01AI087671 · NIAID · UNIVERSITY OF IOWA · PI KERNS, ROBERT JOHN · 2010 to 2014
$1.9M
Synthetic lethality of bicyclomycinR21AI103781 · NIAID · UNIV OF MED/DENT OF NJ-NJ MEDICAL SCHOOL · PI DRLICA, KARL A · 2013 to 2014
$437k
NIAID NIH HHS AI073491-06NIAID NIH HHS AI087671NIAID NIH HHS AI103781-01NIAID NIH HHS R01 AI073491NIAID NIH HHS R01 AI087671NIAID NIH HHS R21 AI103781NIH HHS 1DP2OD007423-01NIH HHS DP2 OD007423
6 · The paper itself

Abstract

backgroundOne way to address the growing problem of antimicrobial resistance is to revive old compounds that may have intrinsic lethal activity that is obscured by protective factors. Bicyclomycin is an old inhibitor of the Rho transcription terminator that by itself shows little rapid lethal activity. However, bicyclomycin participates in bacteriostatic synergy, which raises the possibility that conditions for lethal synergy may exist, perhaps through a suppression of protective factors.

methodsBicyclomycin was combined with bacteriostatic inhibitors of gene expression, and bactericidal activity was measured with several cultured Gram-negative pathogens.

resultsWhen used alone, bicyclomycin failed to rapidly kill growing cultures of Escherichia coli; however, the additional presence of bacteriostatic concentrations of tetracycline, chloramphenicol or rifampicin led to rapid killing. Four other pathogen species, Acinetobacter baumannii, Klebsiella pneumoniae, Salmonella enterica serotype Typhimurium and Shigella dysenteriae, also exhibited enhanced killing when bicyclomycin was combined with tetracycline or rifampicin. This lethal synergy was achieved at low concentrations (slightly above the MIC) for all agents tested in combinations. Follow-up work with E. coli indicated that lethal synergy arose from a blockage of transcription elongation. Moreover, lethal synergy was reduced when bicyclomycin was added 60 min before tetracycline, suggesting that bicyclomycin induces a protective factor.

conclusionsThe action of bicyclomycin illustrates the potential present in a largely abandoned antibacterial agent; it exhibits lethal synergy when coadministered with known, bacteriostatic inhibitors of gene expression. The identification of protective factors, which are currently uncharacterized, may reveal new ways to promote the lethal action of some old antibiotics.

Indexed as

Drug SynergismAnti-Bacterial AgentsBridged Bicyclo Compounds, HeterocyclicGram-Negative BacteriaHumansMicrobial Sensitivity TestsMicrobial ViabilityAnti-Bacterial AgentsbicozamycinBridged Bicyclo Compounds, HeterocyclicAcinetobacter baumanniiback-trackingEscherichia coligene expression inhibitorsKlebsiella pneumoniaetranscription elongation complex

Identifiers

PMID25085655
PMCPMC4228776
OpenAlexW2103510483

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.